Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.51 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15033601 | 0.90 | MAPK1 (0.59) | HPGDALDH1A1SIGMAR1TMEM97MEN1 | |
| SCHEMBL15033599 | 0.85 | ALDH1A1 (0.54) | HPGDALDH1A1ALOX15SIGMAR1TMEM97 | |
| SCHEMBL15038349 | 0.85 | HPGD (0.61) | HPGDALDH1A1POLBKDM4EHTT | |
| SCHEMBL2014524 | 0.81 | HTT (0.52) | HPGDALDH1A1ALOX15SIGMAR1TMEM97 | |
| SCHEMBL15038350 | 0.81 | ALDH1A1 (0.65) | HPGDALDH1A1POLBKDM4E | |
| SCHEMBL15033593 | 0.79 | HPGD (0.62) | HPGDALDH1A1KMT2APOLBKDM4E | |
| SCHEMBL8239624 | 0.79 | HPGD (0.54) | HPGDALDH1A1MEN1KMT2APOLB | |
| SCHEMBL10289215 | 0.78 | ALDH1A1 (0.57) | HPGDALDH1A1KMT2APOLBHTT | |
| SCHEMBL7506575 | 0.77 | HPGD (0.47) | HPGDALDH1A1ALOX15MEN1KMT2A | |
| SCHEMBL14454105 | 0.77 | HPGD (0.47) | HPGDALDH1A1ALOX15MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158112-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BETA AMYLOID SECRETION | CASE WESTERN RESERVE UNIVERSITY | 2013-06-20 | — | — | US | disclosed |
| US-20130158112-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BETA AMYLOID SECRETION | CASE WESTERN RESERVE UNIVERSITY | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158112-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BETA AMYLOID SECRETION | IAPP, APP, BACE1 | HPGD 3327/4885ALDH1A1 4152/4885ALOX15 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.